+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Exocrine Pancreatic Insufficiency Diagnostics Market Size, Share & Trends Analysis Report by Diagnostic Method (Laboratory, Imaging), End-use (Hospitals & Clinics, Research Institutes), Region, and Segment Forecasts, 2024-2030

  • PDF Icon

    Report

  • 125 Pages
  • June 2024
  • Region: Global
  • Grand View Research
  • ID: 5983016
Description Jump to:
The global exocrine pancreatic insufficiency diagnostics market size is anticipated to reach USD 5.44 billion by 2030 and is growing at a CAGR of 7.2% from 2024 to 2030. Exocrine pancreatic insufficiency (EPI) diagnostics are crucial for identifying and managing the condition, especially considering its high prevalence in various patient populations and its association with several underlying causes. One of the major driving factors for diagnostics is the prevalence of patients with chronic pancreatitis. Studies have shown that EPI is prevalent in about 60% to 90% of patients diagnosed with chronic pancreatitis within 10 to 12 years of diagnosis. Chronic pancreatitis is a significant contributor to EPI, and its relatively high prevalence underscores the importance of early detection and management.

Furthermore, advanced pancreatic cancer is another condition strongly associated with the disease. Research indicates that between 66% to 92% of patients with advanced pancreatic cancer develop EPI. Early diagnosis of EPI in these patients can lead to better management of symptoms and improved quality of life. Inflammatory bowel disease (IBD) is also linked to EPI, with studies suggesting that between 14% and 74% of IBD patients may suffer from EPI. Timely diagnosis and treatment of exocrine pancreatic insufficiency in these patients can help alleviate symptoms and improve nutritional status.

In addition, patients undergoing bariatric surgery are at risk of developing EPI despite receiving enzymatic and nutritional supplements. This highlights the importance of ongoing monitoring and diagnostic testing to identify exocrine pancreatic insufficiency in this patient population. Moreover, the prevalence of EPI in patients with HIV/AIDS is estimated to be between 26% and 45%. Early detection of exocrine pancreatic insufficiency in these individuals is essential for optimizing nutritional status and overall health outcomes.

The diverse range of conditions associated with EPI underscores the need for comprehensive diagnostic approaches. Factors driving the demand for exocrine pancreatic insufficiency diagnostics include high prevalence in various patient populations, the association with chronic conditions such as chronic pancreatitis and pancreatic cancer, and the importance of early detection for effective management and improved patient outcomes. As diagnostic technologies advance, early detection and personalized management will become increasingly feasible, leading to better patient care and outcomes.

Key market players such as ChiRhoClin, Inc., Certest Biotec, ScheBo Biotech AG, Immundiagnostik AG, and Laboratory Corporation of America Holdings are at the forefront of innovation in exocrine pancreatic insufficiency diagnostics. These companies are constantly focusing on expanding their products. For instance, in June 2021, CERTEST BIOTEC announced to participate and showcase its product with latest developments at 71st Annual Scientific Meeting and Exhibition of Clinical Laboratories of the AACC held from August 4 to 8 in California.

Exocrine Pancreatic Insufficiency Diagnostics Market Report Highlights

  • Based on diagnostic method, the laboratory tests segment dominated the overall market with the highest revenue share in 2023. This can be attributed to the extensive advancements such as automation in the laboratory, disposable kits, sample collections & storage, and assays
  • Growing R&D in EPI diagnostics is projected to propel market growth over the forecast period
  • The introduction of new techniques and assays and the integration of established technologies signifies a significant step forward in diagnostics. As awareness about pancreatic disorders continues to grow, fueled by advancements in diagnostic technologies, the U.S. market for stool tests in EPI diagnostics is poised for continued expansion in the coming years
  • The hospitals and clinics end-use segment dominated the market in 2023, driven by several factors. Increased awareness among healthcare professionals and patients about symptoms and risk factors has led to higher diagnosis rates in these settings. Accessibility of diagnostic services in hospitals and clinics facilitates widespread screening and testing for exocrine pancreatic insufficiency, and advancements in diagnostic technologies enhance the accuracy and efficiency of EPI detection, further driving growth in this segment
  • North America dominated the market owing to factors such as advanced healthcare infrastructure, rising prevalence of target diseases, and favorable regulatory environment

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets


This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Diagnostic Method
1.2.2. End-use
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Diagnostic method Outlook
2.2.2. End-use Outlook
2.2.3. Regional Outlook
2.3. Competitive Insights
Chapter 3. Exocrine Pancreatic Insufficiency Diagnostics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing disease awareness
3.2.1.2. Focus on early detection
3.2.1.3. Increasing cases of exocrine pancreatic insufficiency
3.2.2. Market Restraint Analysis
3.2.2.1. Regulatory hurdles and compliance requirements
3.2.2.2. Underdiagnosis and misdiagnosis
3.3. Exocrine Pancreatic Insufficiency Diagnostics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Pricing Analysis
3.3.4. Volume Analysis (Laboratory-based Testing Devices)
Chapter 4. Exocrine Pancreatic Insufficiency Diagnostics Market: Diagnostic Method Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global Exocrine Pancreatic Insufficiency Diagnostics Market Movement Analysis
4.3. Global Exocrine Pancreatic Insufficiency Diagnostics Market by Diagnostic Method Outlook
4.4. Laboratory Tests
4.4.1. Laboratory tests market estimates and forecasts 2018-2030 (USD Million)
4.4.2. Indirect Pancreatic Function Tests
4.4.2.1. Market estimates and forecasts 2018-2030 (USD Million)
4.4.2.2. Stool Tests
4.4.2.2.1. Market estimates and forecasts 2018-2030 (USD Million)
4.4.2.3. Blood Tests
4.4.2.3.1. Market estimates and forecasts 2018-2030 (USD Million)
4.4.3. Other Tests
4.4.3.1. Market estimates and forecasts 2018-2030 (USD Million)
4.5. Imaging Tests
4.5.1. Imaging tests market estimates and forecasts 2018-2030 (USD Million)
4.5.2. CT scans
4.5.2.1. Market estimates and forecasts 2018-2030 (USD Million)
4.5.3. MRI
4.5.3.1. Market estimates and forecasts 2018-2030 (USD Million)
4.5.4. Endoscopic Ultrasound for pancreatic function tests
4.5.4.1. Market estimates and forecasts 2018-2030 (USD Million)
Chapter 5. Exocrine Pancreatic Insufficiency Diagnostics Market: End-use Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Global Exocrine Pancreatic Insufficiency Diagnostics Market Movement Analysis
5.3. Global Exocrine Pancreatic Insufficiency Diagnostics Market by End-use Outlook
5.4. Hospitals & Clinics
5.4.1. Hospitals & Clinics market estimates and forecasts 2018-2030 (USD Million)
5.5. Diagnostic Laboratories
5.5.1. Diagnostic laboratories market estimates and forecasts 2018-2030 (USD Million)
5.6. Research Institutes
5.6.1. Research Institutes market estimates and forecasts 2018-2030 (USD Million)
Chapter 6. Exocrine Pancreatic Insufficiency Diagnostics Market: Regional Estimates & Trend Analysis by Diagnostic Method, and End-use
6.1. Regional Dashboard
6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.3. North America
6.3.1. U.S.
6.3.1.1. Key country dynamics
6.3.1.2. Regulatory framework/ reimbursement structure
6.3.1.3. Competitive scenario
6.3.1.4. U.S. market estimates and forecasts 2018-2030 (USD Million)
6.3.2. Canada
6.3.2.1. Key country dynamics
6.3.2.2. Regulatory framework/ reimbursement structure
6.3.2.3. Competitive scenario
6.3.2.4. Canada market estimates and forecasts 2018-2030 (USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Key country dynamics
6.4.1.2. Regulatory framework/ reimbursement structure
6.4.1.3. Competitive scenario
6.4.1.4. UK market estimates and forecasts 2018-2030 (USD Million)
6.4.2. Germany
6.4.2.1. Key country dynamics
6.4.2.2. Regulatory framework/ reimbursement structure
6.4.2.3. Competitive scenario
6.4.2.4. Germany market estimates and forecasts 2018-2030 (USD Million)
6.4.3. France
6.4.3.1. Key country dynamics
6.4.3.2. Regulatory framework/ reimbursement structure
6.4.3.3. Competitive scenario
6.4.3.4. France market estimates and forecasts 2018-2030 (USD Million)
6.4.4. Italy
6.4.4.1. Key country dynamics
6.4.4.2. Regulatory framework/ reimbursement structure
6.4.4.3. Competitive scenario
6.4.4.4. Italy market estimates and forecasts 2018-2030 (USD Million)
6.4.5. Spain
6.4.5.1. Key country dynamics
6.4.5.2. Regulatory framework/ reimbursement structure
6.4.5.3. Competitive scenario
6.4.5.4. Spain market estimates and forecasts 2018-2030 (USD Million)
6.4.6. Denmark
6.4.6.1. Key country dynamics
6.4.6.2. Regulatory framework/ reimbursement structure
6.4.6.3. Competitive scenario
6.4.6.4. Denmark market estimates and forecasts 2018-2030 (USD Million)
6.4.7. Sweden
6.4.7.1. Key country dynamics
6.4.7.2. Regulatory framework/ reimbursement structure
6.4.7.3. Competitive scenario
6.4.7.4. Sweden market estimates and forecasts 2018-2030 (USD Million)
6.4.8. Norway
6.4.8.1. Key country dynamics
6.4.8.2. Regulatory framework/ reimbursement structure
6.4.8.3. Competitive scenario
6.4.8.4. Norway market estimates and forecasts 2018-2030 (USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework/ reimbursement structure
6.5.1.3. Competitive scenario
6.5.1.4. Japan market estimates and forecasts 2018-2030 (USD Million)
6.5.2. China
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework/ reimbursement structure
6.5.2.3. Competitive scenario
6.5.2.4. China market estimates and forecasts 2018-2030 (USD Million)
6.5.3. India
6.5.3.1. Key country dynamics
6.5.3.2. Regulatory framework/ reimbursement structure
6.5.3.3. Competitive scenario
6.5.3.4. India market estimates and forecasts 2018-2030 (USD Million)
6.5.4. Australia
6.5.4.1. Key country dynamics
6.5.4.2. Regulatory framework/ reimbursement structure
6.5.4.3. Competitive scenario
6.5.4.4. Australia market estimates and forecasts 2018-2030 (USD Million)
6.5.5. Thailand
6.5.5.1. Key country dynamics
6.5.5.2. Regulatory framework/ reimbursement structure
6.5.5.3. Competitive scenario
6.5.5.4. Thailand market estimates and forecasts 2018-2030 (USD Million)
6.5.6. South Korea
6.5.6.1. Key country dynamics
6.5.6.2. Regulatory framework/ reimbursement structure
6.5.6.3. Competitive scenario
6.5.6.4. South Korea market estimates and forecasts 2018-2030 (USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework/ reimbursement structure
6.6.1.3. Competitive scenario
6.6.1.4. Brazil market estimates and forecasts 2018-2030 (USD Million)
6.6.2. Mexico
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework/ reimbursement structure
6.6.2.3. Competitive scenario
6.6.2.4. Mexico market estimates and forecasts 2018-2030 (USD Million)
6.6.3. Argentina
6.6.3.1. Key country dynamics
6.6.3.2. Regulatory framework/ reimbursement structure
6.6.3.3. Competitive scenario
6.6.3.4. Argentina market estimates and forecasts 2018-2030 (USD Million)
6.7. MEA
6.7.1. South Africa
6.7.1.1. Key country dynamics
6.7.1.2. Regulatory framework/ reimbursement structure
6.7.1.3. Competitive scenario
6.7.1.4. South Africa market estimates and forecasts 2018-2030 (USD Million)
6.7.2. Saudi Arabia
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework/ reimbursement structure
6.7.2.3. Competitive scenario
6.7.2.4. Saudi Arabia market estimates and forecasts 2018-2030 (USD Million)
6.7.3. UAE
6.7.3.1. Key country dynamics
6.7.3.2. Regulatory framework/ reimbursement structure
6.7.3.3. Competitive scenario
6.7.3.4. UAE market estimates and forecasts 2018-2030 (USD Million)
6.7.4. Kuwait
6.7.4.1. Key country dynamics
6.7.4.2. Regulatory framework/ reimbursement structure
6.7.4.3. Competitive scenario
6.7.4.4. Kuwait market estimates and forecasts 2018-2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. List of key distributors and channel partners
7.3.2. Key customers
7.3.3. Key company market share analysis, 2023
7.3.4. ChiRhoClin
7.3.4.1. Company overview
7.3.4.2. Financial performance
7.3.4.3. Product benchmarking
7.3.4.4. Strategic initiatives
7.3.5. Certest Biotec
7.3.5.1. Company overview
7.3.5.2. Financial performance
7.3.5.3. Product benchmarking
7.3.5.4. Strategic initiatives
7.3.6. ScheBo Biotech AG
7.3.6.1. Company overview
7.3.6.2. Financial performance
7.3.6.3. Product benchmarking
7.3.6.4. Strategic initiatives
7.3.7. Immundiagnostik AG
7.3.7.1. Company overview
7.3.7.2. Financial performance
7.3.7.3. Product benchmarking
7.3.7.4. Strategic initiatives
7.3.8. Laboratory Corporation of America Holdings
7.3.8.1. Company overview
7.3.8.2. Financial performance
7.3.8.3. Product benchmarking
7.3.8.4. Strategic initiatives
7.3.9. Boster Biological Technology
7.3.9.1. Company overview
7.3.9.2. Financial performance
7.3.9.3. Product benchmarking
7.3.9.4. Strategic initiatives
7.3.10. ALPCO Diagnostics
7.3.10.1. Company overview
7.3.10.2. Financial performance
7.3.10.3. Product benchmarking
7.3.10.4. Strategic initiatives
7.3.11. Quest Diagnostics Incorporated
7.3.11.1. Company overview
7.3.11.2. Financial performance
7.3.11.3. Product benchmarking
7.3.11.4. Strategic initiatives
7.3.12. DiaSorin S.p.A.
7.3.12.1. Company overview
7.3.12.2. Financial performance
7.3.12.3. Product benchmarking
7.3.12.4. Strategic initiatives
7.3.13. ARUP Laboratories
7.3.13.1. Company overview
7.3.13.2. Financial performance
7.3.13.3. Product benchmarking
7.3.13.4. Strategic initiatives
7.3.14. Verisana Laboratories
7.3.14.1. Company overview
7.3.14.2. Financial performance
7.3.14.3. Product benchmarking
7.3.14.4. Strategic initiatives
7.3.15. Alpha Laboratories
7.3.15.1. Company overview
7.3.15.2. Financial performance
7.3.15.3. Product benchmarking
7.3.15.4. Strategic initiatives
List of Tables
Table 1 List of abbreviation
Table 2 North America exocrine pancreatic insufficiency diagnostics market, by region, 2018-2030 (USD Million)
Table 3 North America exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018-2030 (USD Million)
Table 4 North America exocrine pancreatic insufficiency diagnostics market, by end-use, 2018-2030 (USD Million)
Table 5 U.S. exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018-2030 (USD Million)
Table 6 U.S. exocrine pancreatic insufficiency diagnostics market, by end-use, 2018-2030 (USD Million)
Table 7 Canada exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018-2030 (USD Million)
Table 8 Canada exocrine pancreatic insufficiency diagnostics market, by end-use, 2018-2030 (USD Million)
Table 9 Europe exocrine pancreatic insufficiency diagnostics market, by region, 2018-2030 (USD Million)
Table 10 Europe exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018-2030 (USD Million)
Table 11 Europe exocrine pancreatic insufficiency diagnostics market, by end-use, 2018-2030 (USD Million)
Table 12 Germany exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018-2030 (USD Million)
Table 13 Germany exocrine pancreatic insufficiency diagnostics market, by end-use, 2018-2030 (USD Million)
Table 14 UK exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018-2030 (USD Million)
Table 15 UK exocrine pancreatic insufficiency diagnostics market, by end-use, 2018-2030 (USD Million)
Table 16 France exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018-2030 (USD Million)
Table 17 France exocrine pancreatic insufficiency diagnostics market, by end-use, 2018-2030 (USD Million)
Table 18 Italy exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018-2030 (USD Million)
Table 19 Italy exocrine pancreatic insufficiency diagnostics market, by end-use, 2018-2030 (USD Million)
Table 20 Spain exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018-2030 (USD Million)
Table 21 Spain exocrine pancreatic insufficiency diagnostics market, by end-use, 2018-2030 (USD Million)
Table 22 Denmark exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018-2030 (USD Million)
Table 23 Denmark exocrine pancreatic insufficiency diagnostics market, by end-use, 2018-2030 (USD Million)
Table 24 Sweden exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018-2030 (USD Million)
Table 25 Sweden exocrine pancreatic insufficiency diagnostics market, by end-use, 2018-2030 (USD Million)
Table 26 Norway exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018-2030 (USD Million)
Table 27 Norway exocrine pancreatic insufficiency diagnostics market, by end-use, 2018-2030 (USD Million)
Table 28 Asia Pacific exocrine pancreatic insufficiency diagnostics market, by region 2018-2030 (USD Million)
Table 29 Asia Pacific exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018-2030 (USD Million)
Table 30 Aisa Pacific exocrine pancreatic insufficiency diagnostics market, by end-use, 2018-2030 (USD Million)
Table 31 Japan exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018-2030 (USD Million)
Table 32 Japan exocrine pancreatic insufficiency diagnostics market, by end-use, 2018-2030 (USD Million)
Table 33 China exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018-2030 (USD Million)
Table 34 China exocrine pancreatic insufficiency diagnostics market, by end-use, 2018-2030 (USD Million)
Table 35 India exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018-2030 (USD Million)
Table 36 India exocrine pancreatic insufficiency diagnostics market, by end-use, 2018-2030 (USD Million)
Table 37 Australia exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018-2030 (USD Million)
Table 38 Australia exocrine pancreatic insufficiency diagnostics market, by end-use, 2018-2030 (USD Million)
Table 39 Thailand exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018-2030 (USD Million)
Table 40 Thailand exocrine pancreatic insufficiency diagnostics market, by end-use, 2018-2030 (USD Million)
Table 41 South Korea exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018-2030 (USD Million)
Table 42 South Korea exocrine pancreatic insufficiency diagnostics market, by end-use, 2018-2030 (USD Million)
Table 43 Latin America exocrine pancreatic insufficiency diagnostics market, by region, 2018-2030 (USD Million)
Table 44 Latin America exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018-2030 (USD Million)
Table 45 Latin America exocrine pancreatic insufficiency diagnostics market, by end-use, 2018-2030 (USD Million)
Table 46 Brazil exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018-2030 (USD Million)
Table 47 Brazil exocrine pancreatic insufficiency diagnostics market, by end-use, 2018-2030 (USD Million)
Table 48 Mexico exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018-2030 (USD Million)
Table 49 Mexico exocrine pancreatic insufficiency diagnostics market, by end-use, 2018-2030 (USD Million)
Table 50 Argentina exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018-2030 (USD Million)
Table 51 Argentina exocrine pancreatic insufficiency diagnostics market, by end-use, 2018-2030 (USD Million)
Table 52 MEA exocrine pancreatic insufficiency diagnostics market, by region, 2018-2030 (USD Million)
Table 53 MEA exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018-2030 (USD Million)
Table 54 MEA exocrine pancreatic insufficiency diagnostics market, by end-use, 2018-2030 (USD Million)
Table 55 South Africa exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018-2030 (USD Million)
Table 56 South Africa exocrine pancreatic insufficiency diagnostics market, by end-use, 2018-2030 (USD Million)
Table 57 Saudi Arabia exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018-2030 (USD Million)
Table 58 Saudi Arabia exocrine pancreatic insufficiency diagnostics market, by end-use, 2018-2030 (USD Million)
Table 59 UAE exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018-2030 (USD Million)
Table 60 UAE exocrine pancreatic insufficiency diagnostics market, by end-use, 2018-2030 (USD Million)
Table 61 Kuwait exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018-2030 (USD Million)
Table 62 Kuwait exocrine pancreatic insufficiency diagnostics market, by end-use, 2018-2030 (USD Million)
List of Figures
Figure 1 Market research process
Figure 2 Data triangulation techniques
Figure 3 Primary research pattern
Figure 4 Primary interviews in North America
Figure 5 Primary interviews in Europe
Figure 6 Primary interviews in Asia Pacific
Figure 7 Primary interviews in Latin America
Figure 8 Primary interviews in MEA
Figure 9 Market research approaches
Figure 10 Value-chain-based sizing & forecasting
Figure 11 QFD modeling for market share assessment
Figure 12 Market formulation & validation
Figure 13 Exocrine pancreatic insufficiency diagnostics market: market outlook
Figure 14 Parent market outlook
Figure 15 Related/ancillary market outlook
Figure 16 Exocrine pancreatic insufficiency diagnostics market driver impact
Figure 17 Exocrine pancreatic insufficiency diagnostics market restraint impact
Figure 18 Exocrine pancreatic insufficiency diagnostics market: Diagnostic method movement analysis
Figure 19 Exocrine pancreatic insufficiency diagnostics market: Diagnostic method outlook and key takeaways
Figure 20 Laboratory tests market estimates and forecast, 2018-2030
Figure 21 Indirect pancreatic function tests market estimates and forecast, 2018-2030
Figure 22 Stool tests market estimates and forecast, 2018-2030
Figure 23 Blood tests market estimates and forecast, 2018-2030
Figure 24 Other tests market estimates and forecast, 2018-2030
Figure 25 Imaging tests market estimates and forecast, 2018-2030
Figure 26 CT scans market estimates and forecast, 2018-2030
Figure 27 MRI market estimates and forecast, 2018-2030
Figure 28 Endoscopic ultrasound for pancreatic function tests market estimates and forecast, 2018 2030
Figure 29 Exocrine pancreatic insufficiency diagnostics market: End-use movement analysis
Figure 30 Exocrine pancreatic insufficiency diagnostics market: End-use outlook and key takeaways
Figure 31 Hospitals & clinics market estimates and forecast, 2018-2030
Figure 32 Diagnostic laboratories estimates and forecast, 2018-2030
Figure 33 Research institutes market estimates and forecast, 2018-2030
Figure 34 Global Exocrine pancreatic insufficiency diagnostics market: Regional movement analysis
Figure 35 Global Exocrine pancreatic insufficiency diagnostics market: Regional outlook and key takeaways
Figure 36 Global Exocrine pancreatic insufficiency diagnostics market share and leading players
Figure 37 North America
Figure 38 North America market estimates and forecasts, 2018-2030 (USD Million)
Figure 39 U.S. key country dynamics
Figure 40 U.S. market estimates and forecasts, 2018-2030 (USD Million)
Figure 41 Canada key country dynamics
Figure 42 Canada market estimates and forecasts, 2018-2030 (USD Million)
Figure 43 Europe
Figure 44 Europe market estimates and forecasts, 2018-2030 (USD Million)
Figure 45 UK key country dynamics
Figure 46 UK market estimates and forecasts, 2018-2030 (USD Million)
Figure 47 Germany key country dynamics
Figure 48 Germany market estimates and forecasts, 2018-2030 (USD Million)
Figure 49 France key country dynamics
Figure 50 France market estimates and forecasts, 2018-2030 (USD Million)
Figure 51 Italy key country dynamics
Figure 52 Italy market estimates and forecasts, 2018-2030 (USD Million)
Figure 53 Spain key country dynamics
Figure 54 Spain market estimates and forecasts, 2018-2030 (USD Million)
Figure 55 Denmark key country dynamics
Figure 56 Denmark market estimates and forecasts, 2018-2030 (USD Million)
Figure 57 Sweden key country dynamics
Figure 58 Sweden market estimates and forecasts, 2018-2030 (USD Million)
Figure 59 Norway key country dynamics
Figure 60 Norway market estimates and forecasts, 2018-2030 (USD Million)
Figure 61 Asia Pacific
Figure 62 Asia Pacific market estimates and forecasts, 2018-2030 (USD Million)
Figure 63 China key country dynamics
Figure 64 China market estimates and forecasts, 2018-2030 (USD Million)
Figure 65 Japan key country dynamics
Figure 66 Japan market estimates and forecasts, 2018-2030 (USD Million)
Figure 67 India key country dynamics
Figure 68 India market estimates and forecasts, 2018-2030 (USD Million)
Figure 69 Australia key country dynamics
Figure 70 Australia market estimates and forecasts, 2018-2030 (USD Million)
Figure 71 Thailand key country dynamics
Figure 72 Thailand market estimates and forecasts, 2018-2030 (USD Million)
Figure 73 South Korea key country dynamics
Figure 74 South Korea market estimates and forecasts, 2018-2030 (USD Million)
Figure 75 Latin America
Figure 76 Latin America market estimates and forecasts, 2018-2030 (USD Million)
Figure 77 Brazil key country dynamics
Figure 78 Brazil market estimates and forecasts, 2018-2030 (USD Million)
Figure 79 Mexico key country dynamics
Figure 80 Mexico market estimates and forecasts, 2018-2030 (USD Million)
Figure 81 Argentina key country dynamics
Figure 82 Argentina market estimates and forecasts, 2018-2030 (USD Million)
Figure 83 Middle East and Africa
Figure 84 Middle East and Africa market estimates and forecasts, 2018-2030 (USD Million)
Figure 85 South Africa key country dynamics
Figure 86 South Africa market estimates and forecasts, 2018-2030 (USD Million)
Figure 87 Saudi Arabia key country dynamics
Figure 88 Saudi Arabia market estimates and forecasts, 2018-2030 (USD Million)
Figure 89 UAE key country dynamics
Figure 90 UAE market estimates and forecasts, 2018-2030 (USD Million)
Figure 91 Kuwait key country dynamics
Figure 92 Kuwait market estimates and forecasts, 2018-2030 (USD Million)
Figure 93 Market share of key market players- Exocrine pancreatic insufficiency diagnostics market

Companies Mentioned

  • ChiRhoClin
  • Certest Biotec
  • ScheBo Biotech AG
  • Immundiagnostik AG
  • Laboratory Corporation of America Holdings
  • Boster Biological Technology
  • ALPCO Diagnostics
  • Quest Diagnostics Incorporated
  • DiaSorin S.p.A.
  • ARUP Laboratories
  • Verisana Laboratories
  • Alpha Laboratories

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages125
PublishedJune 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 3.36 Billion
Forecasted Market Value ( USD ) by 2030 $ 5.44 Billion
Compound Annual Growth Rate7.2%
Regions CoveredGlobal
No. of Companies Mentioned12

Related Topics

Related Reports

Alzheimer's Disease Diagnostics Market Size, Share & Trends Analysis Report by Diagnostics Technique (Biomarkers, Imaging Techniques), Type (Triage, Diagnosis), End-use (Hospitals, Diagnostic Laboratories), Region, and Segment Forecasts, 2024-2030 - Product Image

Alzheimer's Disease Diagnostics Market Size, Share & Trends Analysis Report by Diagnostics Technique (Biomarkers, Imaging Techniques), Type (Triage, Diagnosis), End-use (Hospitals, Diagnostic Laboratories), Region, and Segment Forecasts, 2024-2030

  • Report
  • 150 Pages
  • Global
From
Liver Disease Diagnostics Market Size, Share and Trends Analysis Report by Diagnosis Technique (Imaging, Laboratory Tests, Endoscopy, Biopsy), Disease (NAFLD, NASH, Fibrosis, Cirrhosis), End-use (Hospitals, Laboratories), and Region 2024-2030 - Product Image

Liver Disease Diagnostics Market Size, Share and Trends Analysis Report by Diagnosis Technique (Imaging, Laboratory Tests, Endoscopy, Biopsy), Disease (NAFLD, NASH, Fibrosis, Cirrhosis), End-use (Hospitals, Laboratories), and Region 2024-2030

  • Report
  • 80 Pages
  • Global
From
Global Clinical Lab Automation Market by Product (Liquid Handling, Nucleic Acid Purification System, Microplate Reader, Automated ELISA, Software), End User (Hospital Laboratories, Diagnostic Laboratories) - Forecast to 2030 - Product Image

Global Clinical Lab Automation Market by Product (Liquid Handling, Nucleic Acid Purification System, Microplate Reader, Automated ELISA, Software), End User (Hospital Laboratories, Diagnostic Laboratories) - Forecast to 2030

  • Report
  • 209 Pages
  • Global
From
Thyroid Function Test Market Report by Test Type (TSH Tests, T3 Tests, T4 Tests, and Others), Indication (Hypothyroidism, Hyperthyroidism, Thyroid Cancer, and Others), End User (Hospitals, Diagnostic Laboratories, and Others), and Region 2024-2032 - Product Image

Thyroid Function Test Market Report by Test Type (TSH Tests, T3 Tests, T4 Tests, and Others), Indication (Hypothyroidism, Hyperthyroidism, Thyroid Cancer, and Others), End User (Hospitals, Diagnostic Laboratories, and Others), and Region 2024-2032

  • Report
  • 143 Pages
  • Global
From
Medical And Diagnostic Laboratory Services Global Market Report 2024 - Product Image

Medical And Diagnostic Laboratory Services Global Market Report 2024

  • Report
  • 350 Pages
  • Global
From

About the Exocrine Pancreatic Insufficiency Diagnostics Market

The Exocrine Pancreatic Insufficiency (EPI) Diagnostics market encompasses medical testing methods and devices used to identify and assess the adequate functioning of the exocrine pancreas. EPI is a condition characterized by the insufficient production of digestive enzymes by the pancreas, which can lead to various gastrointestinal symptoms and malabsorption of nutrients. Diagnostics for EPI typically involve measuring the concentration of pancreatic enzymes or the direct function of the pancreas. Common diagnostic methods include fecal elastase tests, fecal fat tests, and direct pancreatic function tests, each aimed at evaluating the pancreas's capability to produce and secrete the enzymes necessary for digestion. Imaging techniques such as endoscopic ultrasound and magnetic resonance imaging (MRI) can also be used to visualize structural changes in the pancreas that may contribute to exocrine dysfunction. The advancement of diagnostics technologies and growing awareness of EPI have led to the development of various testing kits and devices that cater to the needs of healthcare professionals in the diagnosis and management of the condition. Numerous companies operate in the EPI Diagnostics market, offering a range of products and services for the diagnosis of the disease. Some prominent players include Abbott Laboratories, Biohit Oyj, DiaSorin S.p.A., Nordmark Arzneimittel GmbH & Co. KG, and ScheBo Biotech AG. These companies provide a variety of diagnostic solutions, from non-invasive test kits to sophisticated imaging equipment, tailored to improve the accuracy and efficiency of Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.